MicroSert

Company Overview

Snapshot

Founded in July 2010 by Avraham Shekalim, MicroSert operates with 1–10 employees. The company has raised $806K across two funding rounds, with Mayan Ventures participating in one round. MicroSert ceased operations in December 2025.

Business overview

MicroSert develops an easily implantable, refillable, reservoir-type device for long-lasting ocular drug release. Its core technology involves medical-grade elastomeric polymers for sustained and controlled release of biologic medications, capable of being refilled for up to two years after implantation. The company targets the treatment of age-related macular degeneration and diabetic macular edema, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Medical Devices.

Company Intelligence Q&A

What is MicroSert's primary product?

MicroSert develops an intraocular implant designed for sustained drug release within the eye. This device is refillable and can deliver biologic medications for up to two years after implantation.

When was MicroSert founded?

MicroSert was founded in July 2010.

Who are the founders of MicroSert?

Avraham Shekalim is the founder and CEO of MicroSert.

What is the status of MicroSert?

MicroSert is non-active and ceased to operate in December 2025.

What is the total capital raised by MicroSert?

MicroSert raised a total of $806K across two funding rounds.